{"id":253,"date":"2026-01-08T11:22:12","date_gmt":"2026-01-08T11:22:12","guid":{"rendered":"https:\/\/doc.swiss\/?page_id=253"},"modified":"2026-01-09T10:43:52","modified_gmt":"2026-01-09T10:43:52","slug":"invest-in-the-next-phase","status":"publish","type":"page","link":"https:\/\/doc.swiss\/index.php\/invest-in-the-next-phase\/","title":{"rendered":"Invest in the next phase"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>DocSWISS-AI \u2013 The Decision Cockpit That Eliminates Risk <\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">At TRL 4, DocSWISS-AI \u2014 our radiation-tolerant edge-AI vital signs patch \u2014 delivers real-time predictive alerts (target \u226595% accuracy) + a unique retraction strategy that eliminates ongoing risk (QoL\/performance\/safety impact). <strong>As the first CRO with space-validated evidence<\/strong> targeting <strong>fast-track EMA<\/strong>, it avoids massive follow-up costs (unnecessary interventions, liability claims, preventable deaths) at <strong>only ~10% of the avoided expenses<\/strong>. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Market Opportunity<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Global medical wearables: <strong>\u20ac18\u201320B (2025)<\/strong> \u2192 <strong>\u20ac57B+ by 2030 (CAGR ~17%)<\/strong>.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><br>Cross-sector TAM<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Healthcare: <strong>\u20ac1.3\u20137B<\/strong><\/li>\n\n\n\n<li>Defense &amp; Security: <strong>\u20ac4.7B<\/strong><\/li>\n\n\n\n<li>Space: <strong>\u20ac1.5\u20131.7B<\/strong><\/li>\n\n\n\n<li>Industrial Safety: <strong>\u20ac2\u20135B<\/strong><\/li>\n\n\n\n<li>Aviation &amp; Mass Events: High-G triage &amp; safety<\/li>\n\n\n\n<li>Financial\/Insurance &amp; Wellness: <strong>\u20ac12\u201314B<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Business Model &amp; Traction<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Revenue Streams: Device (\u20ac200\u2013400) + subscription (\u20ac15\u201330\/mo) + EuDiPPA brokerage fees.<\/li>\n\n\n\n<li>5-Year Projection: \u20ac450\u2013500M cumulative revenue (base case).<\/li>\n\n\n\n<li>Break-even: Year 2\u20133.<\/li>\n\n\n\n<li>Current Traction: TRL 4 lab-validated prototype, signed MoU\/NDA (EuDiPPA, Digital Health Europe, Prof. C.J. Schilt\/VUB), grant pipeline (EU4Health Jan 2026, Horizon Apr 2026, EIC May 2026).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Unique Value Proposition<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Decision Cockpit<\/strong>: Predictive alerts + retraction strategy eliminates risk exposure.<\/li>\n\n\n\n<li><strong>First-in-Class<\/strong>: Radiation-hardened (&gt;100\u2013300 krad) + sovereign EU data (Rust-based, citizen-owned) + space-validated fast-track EMA pathway.<\/li>\n\n\n\n<li><strong>ROI for Clients<\/strong>: Avoids billions in follow-up costs\/deaths at ~10% expense.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Team &amp; Expertise<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Lean startup with part-time domain experts (high-caliber, low-cost, scalable to full-time):<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Dr. Johannes Petrus Maria (John) Wubbe \u2013 President &amp; Founder (vision\/strategy).<\/li>\n\n\n\n<li>Menno Nijdam \u2013 COO (operations\/execution).<\/li>\n\n\n\n<li>Guilherme (Gon\u00e7alo) Monteiro Ferreira \u2013 Market Access &amp; Pharma (EMA\/payer strategy).<\/li>\n\n\n\n<li>Erwin Wolff \u2013 CTO (Rust\/ICT stack).<\/li>\n\n\n\n<li>Prof. C.J. Schilt (VUB) \u2013 Grant\/University Coordinator (ethics\/governance).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Consortium &amp; Partners<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Signed MoU\/NDA: EuDiPPA (patient brokerage), Digital Health Europe (Partnering 4 Human Health &amp; Performance, Improving Outcomes &amp; Impacts), Prof. C.J. Schilt (VUB \u2013 grant\/university coordinator).<\/li>\n\n\n\n<li>Targeted Discussions: Universities (NL\/CH\/BE\/DE), technical validation, European-level space agencies.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Funding Ask &amp; Use of Funds<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total 2026\u20132028: \u20ac8\u201312M<\/strong> (70\u201380% grants + equity\/debt).<\/li>\n\n\n\n<li><strong>Seed\/Bridge: \u20ac2\u20135M<\/strong> equity\/debt (post-grant traction).<\/li>\n\n\n\n<li>Use of Funds: Prototype scaling, pilots (TRL 5\u20136), EMA dossier, team growth.<\/li>\n\n\n\n<li><strong>Exit Target<\/strong>: Medtech\/defense acquisition<strong> (2029\u20132032)<\/strong>.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Why Invest Now?<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>TRL 4 \u2192 pilots (low entry risk, high upside).<\/li>\n\n\n\n<li>Wearables boom + EHDS push + dual-use demand.<\/li>\n\n\n\n<li>Retraction eliminates risk (first in class).<\/li>\n\n\n\n<li>Space-validated EMA fast-track.<\/li>\n\n\n\n<li>Lean model + strong grant pipeline.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Next Steps<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Download the full Investor Deck or schedule a call:<br><\/strong>Email: <a href=\"mailto:john.wubbe@doc.swiss\">john.wubbe@doc.swiss<\/a><br>Phone: +41 79 946 38 43 <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Thank You<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">DocSWISS AG \u2013 Zurich, Switzerland<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DocSWISS-AI \u2013 The Decision Cockpit That Eliminates Risk At TRL 4, DocSWISS-AI \u2014 our radiation-tolerant edge-AI vital signs patch \u2014 delivers real-time predictive alerts (target \u226595% accuracy) + a unique retraction strategy that eliminates ongoing risk (QoL\/performance\/safety impact). As the first CRO with space-validated evidence targeting fast-track EMA, it avoids massive follow-up costs (unnecessary interventions, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-253","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/pages\/253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/comments?post=253"}],"version-history":[{"count":16,"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/pages\/253\/revisions"}],"predecessor-version":[{"id":355,"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/pages\/253\/revisions\/355"}],"wp:attachment":[{"href":"https:\/\/doc.swiss\/index.php\/wp-json\/wp\/v2\/media?parent=253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}